In transfer learning, the choice of source model largely influences the performance on a target dataset. Still, selecting a fitting source remains a challenging task, especially in medical imaging where one has to decide between models pre-trained on off-the-shelf options, such as ImageNet, and domain specific datasets. Transferability estimation (TE) metrics address this problem by aiming to predict the best performing source model in a computationally cost effective way. However, previous work has reported conflicting TE metric performances due to differences in experimental setups. Moreover, most TE metrics are designed for and evaluated on natural images, while being optimized for accuracy, whereas in medical imaging metrics that are more robust to class imbalance are typically used. We study the impact of varying the target dataset as an isolated factor, by constructing miniature populations of different sample sizes and random seeds. In addition, we investigate the influence of the evaluation metric used to obtain the reference ranking. We find that small modifications to the target dataset change the rankings. Furthermore, we show that the choice of evaluation metric affects the reference rankings and therefore the evaluation of TE metrics. Overall, we observe a low agreement between rankings from TE metrics and reference. The code, model checkpoints and data splits used in this work are available through https://github.com/niclasclassen/robustness-of-transferability-estimation-metrics-for-medical-imaging.
Synthetic histopathology image generation has emerged as an approach that may address data scarcity in computational pathology, yet current evaluation methodologies may not fully assess synthetic data quality for medical applications. This work investigates and addresses limitations in existing evaluation metrics, investigating an approach for assessing synthetic histopathology image quality through domain-specific metrics and downstream task validation. We show that conventional synthetic data evaluation metrics such as Frechet Inception Distance (FID) and Inception Score (IS) may have limitations when applied to histopathology images due to their reliance on ImageNet-pretrained feature extractors. To address these limitations, we propose for consideration modified FID and IS approaches utilizing foundation models pretrained on digital pathology datasets, supplemented by precision-recall based metrics as part of an additional quality assessment. Using conditional denoising diffusion models trained on four benchmark datasets, with a two-step training approach, we generated synthetic datasets with systematically varied quality characteristics. We also measured the correlation between the synthetic data quality metrics with downstream nuclei segmentation performance using common metrics including the aggregated Jaccard index (AJI+) and the Dice coefficient. The study results suggest that pathology-specific metrics may provide improved discriminative power. Specifically, the modified Inception Score indicates higher correlation with downstream task performance (r=0.6096 with AJI+, p=0.0122), compared to the original IS (r=0.0708, p=0.7944). Our observations indicate that increasing the variety of generated training data has a higher positive correlation with segmentation model performance than improving the visual fidelity of individual generated images.
Progress in colonoscopy polyp segmentation is routinely reported through leaderboard comparisons on a small set of public benchmarks. We argue that this apparent progress is difficult to verify: a systematic audit of \textbf{27 papers} published between 2015 and 2026 reveals three structural problems in how the community evaluates models. \textbf{First}, 25 of 27 papers \textit{omit the Hausdorff distance}. Hausdorff distance is a boundary-accuracy metric with direct clinical relevance for detecting flat or small polyps, and is a standard in radiotherapy segmentation. \textbf{Second}, at least five \textit{incompatible train/test split protocols} co-exist across papers reporting results on the same two datasets (Kvasir-SEG and CVC-ClinicDB), making published Dice scores non-comparable even when they appear in the same leaderboard column. \textbf{Third}, 26 of 27 papers make \textit{performance claims without any statistical significance test}. Strikingly, four papers published \emph{after} the Metrics Reloaded framework~\cite{metricsreloaded2024} (Maier-Hein et al., \textit{Nature Methods} 2024) perpetuate these same problems, suggesting that general-purpose metric guidance has not yet reached the colonoscopy sub-community. To show these problems are not merely cosmetic, we re-evaluate five representative models under three controlled protocols with a single uniform scorer, and find that the reported metric conceals large boundary and recall failures, that the ``best'' model changes with the metric, and that near-tied rankings reverse across random splits. We propose a five-point \textbf{Polyp Segmentation Reporting Checklist}~(PSRC) as a lightweight, domain-adapted corrective.
Predicting how a cell's transcriptome responds to a drug it has never seen is a core, hard problem in computational cell biology: recent benchmarks show complex models often fail to beat trivial baselines once test compounds are held out by chemistry. We study one cell line and assay, THP-1 cells profiled by DRUG-seq, scored by the active-compound weighted MSE(wMSE) of the VCPI prediction contest. We propose a staged approach: dumb baselines (untreated control and mean training-compound response) that the field keeps failing to beat; non-parametric retrieval (a Tanimoto-weighted average of a held-out compound's nearest training compounds); and a fusion stage combining a frozen chemistry embedding with retrieval-support features to predict the residual over the mean, with an uncertainty head and gene programs. On the released VCPI THP-1 drug-seq data (14,026 training compounds), under a Bemis-Murcko scaffold split, the model ranking inverts depending on the metric. Under an inverse-variance per-gene proxy, a regularized linear regression on Morgan fingerprints appears to win over the deep models, retrieval, and ChemBERTa -- the textbook "simple baselines win" result. But under the contest's true active-set metric (per-(gene, compound) Mejia weights, validated against the official scorer; mean baseline 0.535 vs the organizers' 0.507 reference), that reverses: the deep models win, our fusion decoder significantly beats the linear fingerprint baseline (-0.012 wMSE, paired bootstrap p < 10^-4), and the proxy's winner becomes the worst chemistry-aware predictor. Picking the metric picks the winner -- to our knowledge the first demonstration on real held-out drug chemistry of the metric-calibration effect established largely on genetic perturbation. We release a reproducible pipeline wired to the official scorer that emits a valid submission over the real 1064 x 12,995 grid.